Intuitive Surgical, Inc. (ISRG) Financial Statements

Intuitive Surgical, Inc.

ISRG · NASDAQ-GS

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$10.06B	$8.35B	$7.12B	$6.22B	$5.71B	$4.36B	$4.48B	$3.72B
Cost of Revenue	$3.42B	$2.72B	$2.39B	$2.03B	$1.75B	$1.50B	$1.37B	$1.12B
Gross Profit	$6.64B	$5.63B	$4.73B	$4.20B	$3.96B	$2.86B	$3.11B	$2.60B
Research & Development	$1.31B	$1.15B	$998.80M	$879.00M	$671.00M	$595.10M	$557.30M	$418.10M
Selling, General & Administrative	$2.38B	$2.14B	$1.96B	$1.74B	$1.47B	$1.22B	$1.18B	$986.60M
Operating Expenses	$3.70B	$3.29B	$2.96B	$2.62B	$2.14B	$1.81B	$1.74B	$1.40B
Operating Income	$2.95B	$2.35B	$1.77B	$1.58B	$1.82B	$1.05B	$1.37B	$1.20B
Other Income / (Expense)	$365.90M	$324.90M	$192.10M	$29.70M	$69.30M	$157.20M	$127.70M	$80.10M
Income Before Taxes	$3.31B	$2.67B	$1.96B	$1.61B	$1.89B	$1.21B	$1.50B	$1.28B
Provision for Income Taxes	$434.80M	$336.30M	$141.60M	$262.40M	$162.20M	$140.20M	$120.40M	$154.50M
Net Income	$2.86B	$2.32B	$1.80B	$1.32B	$1.70B	$1.06B	$1.38B	$1.13B
Basic EPS	$8.00	$6.54	$5.12	$3.72	$4.79	$3.02	$3.98	$9.92
Diluted EPS	$7.87	$6.42	$5.03	$3.65	$4.66	$2.94	$3.85	$9.49
Basic Shares Outstanding	356.90M	355.20M	351.20M	355.70M	356.10M	351.10M	346.20M	113.70M
Diluted Shares Outstanding	362.70M	362.00M	357.40M	362.00M	365.80M	361.00M	358.40M	118.80M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$8.87	$8.61	$9.03	11	↑10 ↓0
Dec 2027	$10.00	$9.74	$10.58	11	↑8 ↓2
Dec 2028	$10.90	$10.90	$10.90	1	↑1 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: ISRG
Type: Stock
Sector: Health Care
Industry: Industrial Specialties
Country: North America
Exchange: NASDAQ-GS

Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.

Key Issues

Bullish view

General surgery and newer specialties are gaining traction, giving Intuitive Surgical additional procedure opportunities beyond its established urology base. Broader adoption could create fresh avenues for long-term procedure growth.

Bearish view

The supplied evidence identifies expansion as an opportunity but does not establish its scale or adoption pace. If newer specialties remain smaller or slower to develop, the expected diversification may not materially offset more mature areas.

Analyst Consensus

See all

Buy

24 analysts

$375

Current

$590

Low

$484

Average

$590

High

Average target implies +29.24% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Pfizer, Inc.PFE · NYSE$25.52